Prophylactic intravesical instillation therapy with adriamycin and mitomycin C in patients with superficial bladder cancer

Tsushima, Tomoyasu; Matsumura, Yosuke; Ozaki, Yujiro; Ye, Jun; Ohmori, Hitoshi

doi:10.1007/bf00262491

Cited by 9 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, 39 patients with superficial G3 bladder cancer but no concomitant CIS who had been treated by TUR initially were analyzed in this study. Details of the patients' characteristics are shown in Table 1. ADJUVANT THERAPY Doxorubicin-based IVC was performed in 17 patients as adjuvant therapy, according to our IVC protocols (10)(11)(12). Bacillus Calmette-Guérin (BCG) therapy was given to four patients postoperatively.…”

Section: Patients' Characteristicsmentioning

confidence: 99%

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy

Sakaguchi¹

2002

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

Section: Patients' Characteristicsmentioning

confidence: 99%

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy

Sakaguchi¹

2002

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…For this reason, we have been investigating the efficacy of intravesical instillation of 100 ml of solution [9]. In the present study, two differ- ent volumes of EPI solution, i.e.…”

Section: Absorption Of Epirubicin Instilled Intravesicallymentioning

confidence: 99%

Absorption of Epirubicin Instilled Intravesically Immediately after Transurethral Resection of Superficial Bladder Cancer

et al. 1998

Self Cite

View full text Add to dashboard Cite

As postoperative adjuvant therapy for superficial bladder cancer, intravesical instillation therapy is commonly conducted. In this case, from the view point of prevention of intraoperative dissemination, commencement of instillation therapy at an early postoperative period is preferred. However, increased drug permeability is suspected because of damage to the bladder mucosa during operation. Therefore, this study was conducted to investigate the plasma level of epirubicin (EPI) instilled immediately after transurethral operation. EPI (20 mg/40 ml or 50 mg/100 ml) was instilled immediately after a transurethral operation, and retained in the bladder for 1 h. Blood samples were obtained before instillation, as well as 30, 60, 120 and 240 min after instillation, and EPI levels were assayed. The mean EPI concentrations (ng/ml) among the 20-mg/40 ml group (n = 5) were <2.5 and <2.0 at 30 and 60 min, respectively, after which they were undetectable. The 50-mg/100 ml group (n = 5) recorded 5.0, 4.4 and <3.0 after 30, 60 and 120 min, respectively, and after 240 min it was undetectable. Intravesical instillation of EPI immediately after a transurethral operation causes a small increase in the plasma level and it is thought to cause small systemic side effects.

show abstract

Superficial bladder cancer: state of the art

Bono

1994

Cancer Chemother. Pharmacol.

View full text Add to dashboard Cite

Prophylactic intravesical instillation therapy with adriamycin and mitomycin C in patients with superficial bladder cancer

Cited by 9 publications

References 7 publications

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy

Absorption of Epirubicin Instilled Intravesically Immediately after Transurethral Resection of Superficial Bladder Cancer

Superficial bladder cancer: state of the art

Contact Info

Product

Resources

About